Tuesday, December 27, 2016

BRIEF-Ose immunotherapeutics signs license agreement with Servier

* Grants Servier license option on exclusive worldwide

rights for development and commercialization of Effi-7

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)